Effects of febuxostat on renal function in patients with chronic kidney disease : A systematic review and meta-analysis
BACKGROUND/OBJECTIVE: Hyperuricemia has been proven to be an independent risk factor for chronic kidney disease (CKD). However, the role of hyperuricemia in the progression of CKD remains unclear. Thus, we performed a systematic review and meta-analysis to evaluate the efficacy and safety of febuxostat, a first line urate-lowering agent, in CKD patients with hyperuricemia.
METHODS: We have systematically searched for randomized controlled trials assessing the efficacy and safety of febuxostat versus control in CKD patients with hyperuricemia through MEDLINE, PubMed, EMBASE, and Cochrane databases. All statistical analyses were conducted by using the statistical package Review Manager, version 5.3.5. Heterogeneity was assessed using the Cochrane Q and I tests and summary statistics were reported with 95% confidence interval. Two-tailed test was used for analysis and a P value of <.05 is considered statistically significant.
RESULTS: Eleven eligible trials with 1317 participants were included in the meta-analysis. A significant reduction in serum uric acid was found in the febuxostat treated group. Also, a significant higher eGFR was found in the febuxostat treated group among CKD stage 3 and 4 patients. No significant difference of major complication or death was identified between treatment and control groups.
CONCLUSIONS: The meta-analysis showed that other than its urate-lowering effect, febuxostat presented a reno-protective effect in CKD patients. More studies with larger sample sizes and higher quality are required to clarify the role of febuxostat use in the progression of CKD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:98 |
|---|---|
| Enthalten in: |
Medicine - 98(2019), 29 vom: 01. Juli, Seite e16311 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lin, Tsu-Chen [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
101V0R1N2E |
|---|
| Anmerkungen: |
Date Completed 31.07.2019 Date Revised 05.10.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1097/MD.0000000000016311 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM299477843 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM299477843 | ||
| 003 | DE-627 | ||
| 005 | 20231225100424.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/MD.0000000000016311 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0998.xml |
| 035 | |a (DE-627)NLM299477843 | ||
| 035 | |a (NLM)31335677 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lin, Tsu-Chen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effects of febuxostat on renal function in patients with chronic kidney disease |b A systematic review and meta-analysis |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.07.2019 | ||
| 500 | |a Date Revised 05.10.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND/OBJECTIVE: Hyperuricemia has been proven to be an independent risk factor for chronic kidney disease (CKD). However, the role of hyperuricemia in the progression of CKD remains unclear. Thus, we performed a systematic review and meta-analysis to evaluate the efficacy and safety of febuxostat, a first line urate-lowering agent, in CKD patients with hyperuricemia | ||
| 520 | |a METHODS: We have systematically searched for randomized controlled trials assessing the efficacy and safety of febuxostat versus control in CKD patients with hyperuricemia through MEDLINE, PubMed, EMBASE, and Cochrane databases. All statistical analyses were conducted by using the statistical package Review Manager, version 5.3.5. Heterogeneity was assessed using the Cochrane Q and I tests and summary statistics were reported with 95% confidence interval. Two-tailed test was used for analysis and a P value of <.05 is considered statistically significant | ||
| 520 | |a RESULTS: Eleven eligible trials with 1317 participants were included in the meta-analysis. A significant reduction in serum uric acid was found in the febuxostat treated group. Also, a significant higher eGFR was found in the febuxostat treated group among CKD stage 3 and 4 patients. No significant difference of major complication or death was identified between treatment and control groups | ||
| 520 | |a CONCLUSIONS: The meta-analysis showed that other than its urate-lowering effect, febuxostat presented a reno-protective effect in CKD patients. More studies with larger sample sizes and higher quality are required to clarify the role of febuxostat use in the progression of CKD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Systematic Review | |
| 650 | 7 | |a Gout Suppressants |2 NLM | |
| 650 | 7 | |a Febuxostat |2 NLM | |
| 650 | 7 | |a 101V0R1N2E |2 NLM | |
| 650 | 7 | |a Uric Acid |2 NLM | |
| 650 | 7 | |a 268B43MJ25 |2 NLM | |
| 700 | 1 | |a Hung, Lie Yee |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Ying-Chun |e verfasserin |4 aut | |
| 700 | 1 | |a Lo, Wei-Cheng |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Chun Hung |e verfasserin |4 aut | |
| 700 | 1 | |a Tam, Ka-Wai |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Mei-Yi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medicine |d 1945 |g 98(2019), 29 vom: 01. Juli, Seite e16311 |w (DE-627)NLM000020737 |x 1536-5964 |7 nnns |
| 773 | 1 | 8 | |g volume:98 |g year:2019 |g number:29 |g day:01 |g month:07 |g pages:e16311 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/MD.0000000000016311 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 98 |j 2019 |e 29 |b 01 |c 07 |h e16311 | ||